Sign in to view content

Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients with nAMD Following a Modified Manufacturing Process

Raj K. Maturi, MD

Video
Published 2019

Related

Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019
Assessing Commercially Available Cell Therapies for Retinal Disease in the U.S.
Ajay E Kuriyan, MD, MS
Daniel Simhaee, MD
Updates from the Field
2018
Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes with Nonexudative AMD Trial (PREVENT): A Prospective Controlled
Maziar Lalezary, MD
Updates from the Field
2018

Category: AMD-Neovascular

See more